Page 1 of 1

Age-related macular degeneration may be linked to quality of dietary carbohydrates

Age-related macular degeneration ( AMD ), one of the leading causes of vision loss in older adults and a person's risk may partly depend upon diet, could be due to quality of carbohydrates, rather than quantity. Their findings were reported in the American Journal of Clinical Nutrition. Taylo...
Read Article

Wet age-related macular degeneration: FDA has approved Lucentis

The FDA ( Food and Drug Administration ) has approved Lucentis ( Ranibizumab injection ) for the treatment of patients with neovascular (wet) age-related macular degeneration ( AMD ). Age-related macular degeneration, a retinal disease causing severe and irreversible vision loss, is a major cause...
Read Article

Wet age-related macular degeneration: FDA has approved Lucentis

The FDA ( Food and Drug Administration ) has approved Lucentis ( Ranibizumab ) for the treatment of patients with neovascular ( wet ) age-related macular degeneration ( AMD ). The FDA approval of Lucentis is based on data from two large Phase III clinical trials ( MARINA and ANCHOR ). In these s...
Read Article

High levels of homocysteine may be linked to increased age-related macular degeneration risk

People who have elevated homocysteine in their blood, an amino acid that is a known biomarker for cardiovascular disease, may also be at an increased risk of developing age-related macular degeneration ( AMD ). The study is published in the American Journal of Ophthalmology. This research was ...
Read Article

Early treatment of macular degeneration with Macugen may help patients preserve their vision

Age-related macular degeneration ( AMD ) is the leading cause of blindness in older patients in the developed world. Vascular endothelial growth factor is one of the key mediators stimulating the abnormal blood vessel growth and leakage characteristic of the exudative ( wet ) form of the conditi...
Read Article

Novartis, new products portfolio

Novartis has a comprehensive portfolio of cardiovascular products both in the market ( Diovan and Lotrel ) as well as in development ( such as LAF237 and SPP100 ), for the treatment of hypertension, dyslipidemia and diabetes. Other compounds in development include APP018 ( D-4F ), an oral Apo A-1...
Read Article

Wet AMD, Lucentis and Visudyne combination maintains or improves vision in 90% of patients

A single-masked Phase I/II clinical study of the investigational drug Lucentis ( Ranibizumab ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degeneration ( AMD ) when used in combination with Verteporfin ( Visudyne ) photodynamic therapy ( PDT ). ...
Read Article